Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL™/LAL+ ®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first ...

Ron Kurtz, Chief Executive Officer and President of RxSight, said, “Given RxSight’s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...

RxSight (RXST) stock plunged 28% as the MedTech firm cut full-year guidance and issued disappointing early Q1 results, citing market challenges. Read more here.

These factors led to a year-over-year decline in same-store sales of Light Adjustable Lenses (LALs ... clinical data to highlight the benefits of RxSight’s adjustable IOL platform.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device ... driven by: The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic ... The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume ...

The brokerage highlighted that RxSight’s first-quarter performance saw a sequential revenue decline of around 6% compared to the fourth quarter of 2024. Sales of Light Adjustable Lenses (LALs ...